Heparin-induced platelet dysfunction and cardiopulmonary bypass

Annals of Thoracic Surgery

Volumn 69, Issue 6, 2000, Pages 1827-1832

  Muriithi, Elijah W ^a   Belcher, Philip R ^a   Day, Stephen P ^a   Menys, Valentine C ^a   Wheatley, David J ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN;

ARTICLE; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; DRUG MECHANISM; EXTRACORPOREAL CIRCULATION; HEPARINIZATION; HUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE DYSFUNCTION;

BLOOD PLATELET DISORDERS; BLOOD PLATELETS; CARDIOPULMONARY BYPASS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMODILUTION; HEPARIN; HUMANS; PLATELET AGGREGATION;

EID: 0033922114     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(00)01299-6     Document Type: Article

References (24)

1. Belisle S., Hardy J.F. Hemorrhage and the use of blood products after adult cardiac operations myths and realities . Ann Thorac Surg. 62:1996;1908-1917.
2. Kestin A.S., Valeri C.R., Khuri S.F., et al. The platelet function defect of cardiopulmonary bypass. Blood. 82:1993;107-117.
3. Khuri S.F., Valeri R., Loscalzo J., et al. Heparin causes platelet dysfunction and induces fibrinolysis before cardiopulmonary bypass. Ann Thorac Surg. 60:1995;1008-1014.
4. Belcher PR, Muriithi EW, Milne EM, Wanikiat P, Wheatley DJ, Armstrong RA. Heparin, platelet aggregation, neutrophils and cardiopulmonary bypass. Thromb Res 2000 (in Press).
5. Pedvis L.G., Wong T., Frojmovic M.M. Differential inhibition of the platelet activation sequence shape change, micro- and macro-aggregation, by a stable prostacyclin analogue (Iloprost) . Thromb Haemost. 59:1988;323-328.
6. Menys V.C., Belcher P.R., Noble M.I., et al. Macroaggregation of platelets in plasma, as distinct from microaggregation in whole blood (and plasma), as determined using optical aggregometry and platelet counting respectively, is specifically impaired following cardiopulmonary bypass in man. Thromb Haemost. 72:1994;511-518.
7. Kawahito K., Kobayashi E., Iwasa H., Misawa Y., Fuse K. Platelet aggregation during cardiopulmonary bypass evaluated by a laser light-scattering method. Ann Thorac Surg. 67:1999;79-84.
8. Besterman E.M., Gillett M.P. Heparin effects on plasma lysolecithin formation and platelet aggregation. Atherosclerosis. 17:1973;503-513.
9. Novotny W.F., Maffi T., Mehta R.L., Milner P.G. Identification of novel heparin-releasable proteins, as well as the cytokines midkine and pleiotrophin, in human postheparin plasma. Arterioscler Thromb. 13:1993;1798-1805.
10. Mackie I.J., Jones R., Machin S.J. Platelet impedance aggregation in whole blood and its inhibition by antiplatelet drugs. J Clin Pathol. 37:1984;874-878.
11. Johnson M.F., Davis R.B. Effects of blood dilution on electrical impedance aggregometry. Thromb Res. 42:1986;855-857.
12. Abbate R., Boddi M., Prisco D., Gensini G.F. Ability of whole blood aggregometer to detect platelet hyperaggregability. Am J Clin Pathol. 91:1989;159-164.
13. Born G.V., Hume M. Effects of the numbers and sizes of platelet aggregates on the optical density of plasma. Nature. 215:1967;1027-1029.
14. Storey R.F., Wilcox R.G., Heptinstall S. Differential effects of glycoprotein IIb/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonist potency. Implications for assay methodology and comparison of different antagonists. Circulation. 98:1998;1616-1621.
15. Charo I.F., Feinman R.D., Detwiler T.C. Interrelations of platelet aggregation and secretion. J Clin Invest. 60:1977;866-873.
16. Heiden D., Mielke C.H.J., Rodvien R. Impairment by heparin of primary haemostasis and platelet [14C]5-hydroxytryptamine release. Br J Haematol. 36:1977;427-436.
17. Barrowcliffe T.W., Merton R.E., Gray E., Thomas D.P. Heparin and bleeding an association with lipase release . Thromb Haemost. 60:1988;434-436.
18. Harker L.A., Malpass T.W., Branson H.E., Hessel E.A., Slichter S.J. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass acquired transient platelet dysfunction associated with selective alpha-granule release . Blood. 56:1980;824-834.
19. Dawes J., Pumphrey C.W., McLaren K.M., Prowse C.V., Pepper D.S. The in vivo release of human platelet factor 4 by heparin. Thromb Res. 27:1982;65-76.
20. Karlsson K., Marklund S.L. Heparin-induced release of extracellular superoxide dismutase to human blood plasma. Biochem J. 242:1987;55-59.
21. Malmstrom R., Packard C.J., Caslake M., et al. Effect of heparin-stimulated plasma lipolytic activity on VLDL APO B subclass metabolism in normal subjects. Atherosclerosis. 146:1999;381-390.
22. Despotis G.J., Joist J.H., Hogue C.W.J., et al. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg. 110:1995;46-54.
23. Siafaka-Kapadai A., Hanahan D. An endogenous inhibitor of PAF-induced platelet aggregation, isolated from rat liver, has been identified as free fatty acid. Biochim Biophys Acta. 1166:1993;217-221.
24. Besterman E.M., Gillett M.P. A comparison of the effects of saturated and polyunsaturated lysolecithin fractions on platelet aggregation and erythrocyte sedimentation. Atherosclerosis. 16:1972;89-94.